PO-421 A novel high-throughput drug screening platform using pancreatic ductal adenocarcinoma derived organoids in the organoplate®

Abstract

Introduction Pancreatic cancer is one of the deadliest tumours due to the limited treatment options and late diagnosis. Here, we describe a novel high throughput drug screening platform combining the OrganoPlate, a microfluidic based 3D-culture plate, and the recently described Pancreatic Ductal AdenoCarcinoma (PDAC) derived organoids. Material and methods The OrganoPlate is a high throughput microfluidic 3D cell culture platform, supporting physiologically relevant models with a minimal requirement of cell material and enabling a wide range of flow and co-culture options (e.g. with blood vessels). Organoids were derived from human PDAC xenografts and seeded in the OrganoPlate. The low amount of tissue material required (4000 cells per chip) and the high number of replicates on one plate (n=96 on a standard microtiter format plate) renders the OrganoPlate an efficient and cost-effective platform for drug screening and toxicity assays on complex, 3D models. Results and discussions Organoids were exposed to various chemotherapeutic drugs for 72 hours. The viability of the organoids before and after drug treatment is monitored with standard viability assays and subsequently used to generate dose response curves. Conclusion In conclusion, we showed that the OrganoPlate can be used for high throughput drug screening assays and toxicity screening, and demonstrated its compatibility with human pancreatic PDAC derived organoids.